DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR NARCAN
» See Plans and Pricing
All Clinical Trials for Narcan
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00335517 | Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients | Completed | EKR Therapeutics, Inc | N/A | 2006-06-01 | The purpose of the study is to help determine the appropriate dose of DepoDur for use in spinal surgery. The study will also assess the safety of this drug in this patient population. |
| NCT00335517 | Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients | Completed | University of Rochester | N/A | 2006-06-01 | The purpose of the study is to help determine the appropriate dose of DepoDur for use in spinal surgery. The study will also assess the safety of this drug in this patient population. |
| NCT00799201 | Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients | Terminated | CAMC Health System | Phase 4 | 2007-08-01 | The purpose of this study is to determine if enteral naloxone is more effective than a traditional bowel regimen in the prevention and treatment of constipation and impaired gastric motility in critically ill trauma patients. |
| NCT00947284 | Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity | Terminated | University of California, San Francisco | N/A | 2010-01-01 | In previous clinical studies of post-surgical pain the investigators found that nalbuphine (Nubain), a narcotic pain killer, relieves pain more effectively when combined with low-dose naloxone (Narcan), a drug that is used to treat narcotic overdose. This finding was particularly true in men. The purpose of this study is to find out if nalbuphine combined with naloxone is more effective in relieving experimentally produced pain than either drug alone. A second reason for this study is to find out if study medications work more effectively in women or in men. Subjects will come to the University of California at San Francisco (UCSF) Clinical Research Center (CRC) for 4 study visits. The first visit will be a 2-hour screening to assess the subject for study eligibility. During the other three visits, the investigators will use a thermal stimulating device to produce temporary, non-injurious skin sensitivity that subjects will feel as painful. Changes in pain will be measured following the intravenous (i.v.) administration of study drugs. Three drug combinations will be administered, a different one each visit: 1) nalbuphine 5 mg and naloxone 0.4 mg , 2) naloxone 0.4 mg and saline (an inactive solution), nalbuphine 5 mg and saline. These drug combinations will be administered in random order; all subjects will receive all three combinations. |
| NCT01912573 | Nasal Naloxone for Narcotic Overdose | Unknown status | Judith Feinberg | Phase 4 | 2013-09-01 | The goal of this study is to determine if nasal naloxone is inferior to standard care for naloxone administration in a pre-hospital setting. Ambulance squads in Adams, Clermont, and Scioto counties in southern Ohio will be randomized to provide either standard care or nasal (IN) naloxone as the initial response to a suspected opioid overdose. Standard care includes administration of naloxone by intravenous (IV), intramuscular (IM) or intraosseus (IO) methods. |
| NCT02700048 | Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia | Active, not recruiting | University of Minnesota - Clinical and Translational Science Institute | Phase 1/Phase 2 | 2016-06-01 | This is a single center, single-blind randomized cross over design trial that will compare the impact of intra-nasal naloxone vs. intra-nasal saline administration during experimental hypoglycemia on day one on responses to experimental hypoglycemia on day two. Investigators intend to enroll 18 individuals to obtain the complete data sets from 15 participants. Expected duration of subject participation is 10-12 weeks. This study will consist of two 2-day intervention visits separated by approximately 8 weeks. |
| NCT02922959 | A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses | Not yet recruiting | National Institute on Drug Abuse (NIDA) | N/A | 2017-04-01 | This project will further develop and test the Tailored Telephone Intervention delivered by Peers to Prevent Recurring Opioid Overdoses (TTIP-PRO), a promising, low-cost, intervention to facilitate entry into medication assisted treatment (MAT) for individuals experiencing a non-fatal opioid overdoses (OOD). A prior small-scale pilot/feasibility study of TTIP-PRO (NCT02282306) found that the participating patients and the Peer Interventionists were satisfied with their participation, the intervention was acceptable, and the system for generating patient-tailored intervention information performed well. The overall goal of the present study is to conduct a pilot randomized controlled trial of TTIP-PRO versus a control group. It is hypothesized that patients in the TTIP-PRO group will have more favorable drug-abuse-related outcomes than patients in the control group. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Narcan
Condition Name
Clinical Trial Locations for Narcan
Trials by Country
Clinical Trial Progress for Narcan
Clinical Trial Phase
Clinical Trial Sponsors for Narcan
Sponsor Name
